profit from every ₹100 of sales.
₹0₹100
Sun Pharma Advanced Research
₹206.50-2.75% today
+57.9% in 1 year
1-year low ₹108.711-year high ₹277.57
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
You pay ₹4.31 for every ₹1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Sun Pharma Advanced Research sold, what it kept, and what it did with the cash.
Sales went from ₹2.39 billion in 2023 to ₹18.8 billion in 2026, with ₹15.5 billion of profit last year.
SalesProfit
Sun Pharma Advanced Research vs. similar companies
Sun Pharma Advanced Research grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from ₹100 of sales | Sales growth a year | Price per ₹1 of profit |
|---|---|---|---|
| Sun Pharma Advanced Research | 4.3× · Cheap | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Sun Pharma Advanced Research's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 2,388 | 755 | 718 | 18,792 | |
| 620 | -602 | -327 | 18,329 | |
| -2,236 | -4,115 | -3,355 | 15,886 | |
| -2,032 | -3,731 | -3,214 | 15,974 | |
| -2,226 | -3,872 | -3,425 | 15,532 | |
| -7.82 | -11.93 | -10.55 | 47.86 | |
| 26.0% | -79.7% | -45.5% | 97.5% | |
| -93.7% | -544.7% | -467.5% | 84.5% | |
| -93.2% | -512.6% | -477.2% | 82.7% |
Balance sheet
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 8,301 | 5,150 | 3,355 | 21,709 |
| Cash | 6 | 53 | 20 | 12 |
| Total debt | 157 | 577 | 2,651 | 5,593 |
| Total liabilities | 3,174 | 3,893 | 5,525 | 8,320 |
| 5,128 | 1,258 | -2,169 | 13,388 | |
| 285 | 325 | 325 | 325 | |
| -30.5% | -157.7% | -519.4% | 62.7% | |
| -43.4% | -307.9% | 157.9% | 116.0% |
Cash flow
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| -691 | -4,292 | -3,603 | -2,388 | |
| 154 | 265 | 103 | 238 | |
| -845 | -4,557 | -3,706 | -2,626 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| – | – | – | – |
Valuation
- 4.3×
- –
- –
- 4.9×
- 3.6×
- –
- 4.5×
- -3.9%
- 23.2%
- –
Profitability
- 97.5%
- 84.5%
- 82.7%
- –
- 62.7%
- -161.2%
- –
- –
- –
- –
Growth
- +98.9%
- –
- –
- –
- +4.5%
Financial health
- 0.3×
- 0.42
- –
- 46.5×
- 2.47
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 1%of 963
Top 1%of 894
Top 2%of 632
Top 5%of 908
Bottom 19%of 991
News
The Healthcare ETF Showdown: Broad Global Health or Targeted Pharma Power?Yahoo Finance · Nov 7, 2026Nuvectis Pharma, Inc. Q3 2026 Earnings Call SummaryYahoo Finance · Nov 4, 2026Royalty Pharma plc Q3 2026 Earnings Call SummaryYahoo Finance · Nov 4, 20263 Reasons Royalty Pharma Is a Dividend Stock You Never Have to SellYahoo Finance · Oct 22, 2026Stock Market Today: Dow Rises As Oil Prices Back Off; Biotech, Pharma Stocks Shine (Live Coverage)Yahoo Finance · Oct 20, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
7/7Passes 7 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
63Pass
Benjamin Graham
63Pass
Philip Fisher
74Pass
Peter Lynch
100Pass
Joel Greenblatt
100Pass
Charlie Munger
69Pass
Terry Smith
68Pass
Questions about Sun Pharma Advanced Research
Is Sun Pharma Advanced Research a good stock to buy?
A strong, very profitable business, and the price looks low. 7 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Sun Pharma Advanced Research AI analysis
What does Sun Pharma Advanced Research do?
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. It is in Drug Manufacturers - Specialty & Generic, based in Mumbai, India.
Is Sun Pharma Advanced Research stock halal?
Yes. Sun Pharma Advanced Research passes our halal screen: its business is permitted and its debt is 8% of its market value, under the 30% limit. How we check
How has Sun Pharma Advanced Research stock done over the past year?
Up 57.9% over the past twelve months, to ₹206.50. It traded between ₹108.71 and ₹277.57 and is 25.6% below its high.
Who are Sun Pharma Advanced Research's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Sun Pharma Advanced Research's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.